Lv31
210 积分 2025-04-30 加入
Evolving roles of MET as a therapeutic target in NSCLC and beyond
2小时前
已完结
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
2小时前
已完结
Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies
2个月前
已完结
OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
2个月前
已关闭
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
3个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
3个月前
已完结
皖公网安备34019202002308
